IBM, Accelrys join hands to boost drug development
Wednesday, 20 February, 2002
IBM and software developer Accelrys have announced an alliance aimed at developing collaborative applications that will help pharmaceutical companies shorten the development cycles for new drugs.
The partnership with IBM will help Accelrys speed the release of its Discovery Studio platform, the companies said. No release date was given for Discovery Studio.
Discovery Studio is designed to shorten the drug development cycle by allowing researchers to capture and re-use scientific data that is generated by a range of sources, including Accelrys life sciences applications as well as software products developed by third parties. To help make this possible, Accelrys will incorporate support for IBM's DiscoveryLink data integration technology in Discovery Studio, the companies said.
Under terms of the four-year alliance, announced on Monday, Accelrys will use a range of high-end servers from IBM for software development, testing and knowledge management applications. As part of the alliance, IBM and Accelrys will also offer joint consulting and implementation services to deploy systems based on products from the two companies.
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
Newborns have elevated levels of an Alzheimer's biomarker
What do the brains of newborns and patients with Alzheimer's disease have in common? Both...
Cannabis use may double risk of cardiovascular disease death
Cannabis users have a 29% higher risk of acute coronary syndrome, a 20% higher risk of stroke,...
